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promising results in the treatment of cancer, but they still
need to overcome various hurdles, including a complicated
manufacturing process. Receptor-targeted lentiviral vectors
(LVs) delivering genes selectively to T cell subtypesmay facilitate
and improve CART cell generation, but so far they have resulted
in lower gene delivery rates than conventional LVs (vesicular
stomatitis virus [VSV]-LV). To overcome this limitation, we
studied the effect of the transduction enhancer Vectofusin-1
on gene delivery to human T cells with CD4- and CD8-targeted
LVs, respectively, encoding a second-generation CD19-CAR in
conjunction with a truncated version of the low-affinity nerve
growth factor receptor (DLNGFR) as reporter. Vectofusin-1
significantly enhanced the gene delivery of CD4- and CD8-LVs
without a loss in target cell selectivity and killing capability of
the generated CAR T cells. Notably, delivery rates mediated by
VSV-LV were substantially reduced by Vectofusin-1. Interest-
ingly, a transient off-target signal in samples treated with Vecto-
fusin-1 was observed early after transduction. However, this
effect was not caused by uptake and expression of the transgene
in off-target cells, but rather it resulted from cell-bound LV par-
ticles havingDLNGFR incorporated into their surface. The data
demonstrate that gene transfer rates in the range of those medi-
ated by VSV-LVs can be achieved with receptor-targeted LVs.Received 8 October 2018; accepted 11 March 2019;
https://doi.org/10.1016/j.omtm.2019.03.003.
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Nowadays, the combination of gene therapy and immunotherapy for
the treatment of cancer becomes a true and realistic addition to clas-
sical surgery, radiotherapy, or chemotherapy. In 2017, two therapies
relying on the genetic manipulation of autologous T cells with a
chimeric antigen receptor (CAR) for the treatment of advanced blood
cancers were granted marketing authorization by the U.S. Food and
Drug Administration (FDA) and recently also the European Com-
mission (EC).1 Lentiviral vectors (LVs) are one of the most applied
vehicles for CAR gene delivery into human T cells.2
Commonly, LVs are pseudotyped with the glycoprotein of the vesic-
ular stomatitis virus (VSV-G) or with the envelope proteins ofMolecular Therapy: Methods &
This is an open access article under the CC BY-NC-g-retroviruses (g-RVs), such as murine leukemia virus (MLV) or
gibbon ape leukemia virus (GALV), and, more recently, the baboon
endogenous retrovirus (BaEV), resulting in vector particles with a
broad tropism mediating gene transfer into basically all human cell
types.3 In contrast, receptor-targeted LVs aim at delivering genes
exclusively to a cell population of choice. This can be achieved by
permanent ablation of natural receptor binding of the pseudotyped
envelope proteins and genetic fusion of a targeting ligand recognizing
a specific cell surface antigen.4 With this concept, LVs exclusively
targeting distinct cell types of the hematopoietic system, tumor cells,
pluripotent cells, or cells of the CNS were already generated.4 Of
these, LVs retargeted to human CD4 and CD8, respectively, were
proven to deliver genes selectively to the respective T cell subtypes
in vitro and in vivo.5–7
While the CD8-targeted vector (CD8-LV) was pseudotyped with
modified envelope proteins of Nipah virus (NiV) fused to a CD8-
specific single chain variable fragment (scFv), the CD4-targeted LV
(CD4-LV) contained modified envelope proteins of measles virus
(MV) fused to a CD4-specific designed ankyrin repeat protein
(DARPin).5,6 Both LVs have been shown to deliver reporter genes as
well as therapeutic genes, including T cell receptors (TCRs) and
CARs, with high selectivity into the targeted T lymphocyte cell popu-
lation.6,7 In this respect, CD8-LV and CD4-LV could mediate subtype-
specific T cell manipulation without the need for prior cell separation,
and, thus, they facilitate and improve CAR T cell generation. However,
before these LVs can be applied to manufacturing, their gene delivery
rates must be improved to come close to those of VSV-LVs.
Transduction enhancers are commonly used to boost vector cell entry
by facilitating efficient co-localization of vectors and cells. TheseClinical Development Vol. 13 June 2019 ª 2019 The Author(s). 371
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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polybrene, protamine sulfate) or even small molecules (e.g., fibro-
nectin).8 More recently, Vectofusin-1, a histidine-rich cationic
amphipathic short peptide, was discovered promoting the transduc-
tion of human CD34-positive hematopoietic stem cells with various
pseudotyped LVs.9 Interestingly, for human T and B cells, enhanced
transduction using Vectofusin-1 was observed for LVs pseudotyped
with the envelope protein of GALV, but not VSV-G.10
Here we investigated the effect of Vectofusin-1 on CD4-LV and
CD8-LV along with VSV-LV and LVs pseudotyped with the glyco-
protein of BaEV (BaEV-LV) for the delivery of a second-generation
CD19-CAR to human T cells. To facilitate the detection of the CAR
transgene, the transfer vector encoded a truncated version of the
low-affinity nerve growth factor receptor (DLNGFR) as reporter.
We show that Vectofusin-1 significantly enhanced gene delivery
mediated by BaEV-LV and, notably, also CD4-LV and CD8-LV,
without compromising target cell selectivity. We detected, however,
a transient delivery of DLNGFR as protein to target and off-target
cells upon vector particle addition.
RESULTS
Vectofusin-1 Augments CAR-Gene Transfer Rates by CD4- and
CD8-Targeted LVs
Four types of CD19-CAR-encoding LVs were produced, besides tar-
geted CD4-LV and CD8-LV also the non-targeted VSV-LV and
BaEV-LV, each in several batches. All vectors encoded a second-gen-
eration CD19-specific CAR11 and the reporter protein DLNGFR
linked by a P2A cleavage site (Figure 1A). The generated LV particles
were used to transduce interleukin-2 (IL-2)-stimulated human
peripheral blood mononuclear cells (PBMCs) in the presence or
absence of Vectofusin-1. Transduction was analyzed 12 days later
using flow cytometry by staining the cells for the reporter DLNGFR
as well as CD4 or CD8.
In the presence of Vectofusin-1, the number of CD4-positive cells
transduced by CD4-LV was enhanced more than 2-fold from 22%
to 57% (Figure 1B). This effect of Vectofusin-1 was even more pro-
nounced for CD8-LV, where the transduction rate of CD8-positive
cells increased from 32% to 87% (Figure 1B). Importantly, receptor
specificity was retained for both retargeted vectors. The low amount
of stained receptor-negative DLNGFR-positive cells was at the back-
ground level of untransduced cells (Figure 1B). In contrast, transduc-
tion with VSV-LV in the presence of Vectofusin-1 was diminished
when compared to the sample without transduction enhancer (Fig-
ure 1B). With Vectofusin-1 only, 21% and 13% of the CD4- and
CD8-positive cells were transduced, while without Vectofusin-1
transduction rates of 52% and 33% were achieved, respectively. The
highest overall transduction rate was achieved using BaEV-LV, reach-
ing 62% and 45% of CD4- and CD8-positive cells in the absence and
79% and 66% in the presence of Vectofusin-1, respectively.
To investigate whether this observed effect of Vectofusin-1 was inde-
pendent from the used donor, the PBMC activation conditions, or the372 Molecular Therapy: Methods & Clinical Development Vol. 13 June 2particular vector batch, transduction was performed several times
with varying donors, under two different PBMC stimulation proto-
cols, and with two to five vector productions for each vector type.
Notably, the different vector types contained reproducibly similar
particle numbers (Table S1).
The transduction experiments revealed that Vectofusin-1 improved
transgene delivery for CD4-LV, CD8-LV, and BaEV-LV substantially
and was detrimental for VSV-LV (Figure 1C). On average, transduc-
tion of CD4- or CD8-positive T cells in the presence of Vectofusin-1
with CD4-LV or CD8-LV increased from approximately 50% to 80%,
with no impact on vector specificity. For BaEV-LV, enhancements
from about 60% to 85% for CD4-positive cells and 50% to 85% for
CD8-positive cells were observed. In contrast, 75% of CD4-positive
and 55% of CD8-positive cells were transduced with VSV-LV in
the absence of Vectofusin-1, which decreased to 40% (CD4+) and
30% (CD8+) in the presence of Vectofusin-1.
When we analyzed the cells by flow cytometry for DLNGFR expres-
sion at earlier time points than day 12, we detected DLNGFR-positive
cells in some samples that were transduced with CD4-LV or CD8-LV
not only in target receptor-positive but also in target receptor-
negative cells. One example in which this effect was particularly
pronounced is shown in Figure S1. The off-target signals disappeared
after prolonged cultivation of the cells. For CD4-LV, we observed
about 60% of CD4-negative cells showing a signal for DLNGFR on
day 5 post-transduction, which disappeared to background level on
day 13. Similarly, for CD8-LV, about 20% DLNGFR-positive but
CD8-negative cells were present on day 5, which decreased to 0.8%
DLNGFR-positive, CD8-negative cells on day 13. The transient
off-target staining for DLNGFR in the presence of Vectofusin-1 was
also observed in some samples for CD4-CD8 double-negative cells,
which were likely monocytes, B lymphocytes, or granulocytes (Fig-
ure S1C). Notably, these cells were present in all PBMC cultures to
a donor variable amount to the same extent at early and late analysis
time points (Figure S1D). Death of DLNGFR-positive cells other than
T cells between days 5 and 13 during cultivation could, therefore, be
excluded as explanation for the absence of DLNGFR-positive off-
target cells at day 13. Rather, transfer of DLNGFR as protein from
packaging cells to PBMCs could be an explanation for these observa-
tions (see below).
Vectofusin-1 Did Not Impair the Killing Capability of the
Generated CAR T Cells
We next assessed whether the transduction enhancer had an influence
on the viability, proliferation capacity, or phenotype of the transduced
T cells. No significant difference in T cell viability was observed upon
transduction with receptor-targeted VSV- or BaEV-pseudotyped
particles (Figure S2A). With regard to proliferation capacity,
Vectofusin-1 appeared to slightly impact the growth of PBMCs at least
in some samples, including untransduced cells (Figure S2B). Analysis
of the amount of naive (TN), stem cell memory (TSCM), effector mem-
ory (TEM), central memory (TCM), or effector (TEFF) T lymphocytes
present in the CD8-positive or CD4-positive PBMC fraction 13 days019
Figure 1. CAR Gene Delivery with Different Lentiviral Vectors in the Presence and Absence of Vectofusin-1
(A) Schematic representation of the CAR construct. The second-generation CAR consists of a CD19-scFv derived from the murine monoclonal antibody FMC63, a human
CD8-derived hinge and transmembrane domain, the 4-1BB co-stimulatory domain, and a CD3z-signaling domain. The reporter protein DLNGFR is connected to the CAR
gene by a P2A peptide self-cleavage sequence. Transgene expression is under the control of the human phosphoglycerate kinase (PGK) promoter. The woodchuck hepatitis
virus posttranscriptional regulatory element (WPRE) encoded after a stop codon promotes enhanced transgene expression. (B) IL-2-stimulated human PBMCs were
transduced with 5 mL CD4-LV, CD8-LV, or VSV-LV or 1 mL BaEV-LV in the presence or absence of Vectofusin-1 (V1) or left untransduced. Then 12 days later, flow cytometry
was performed after staining the cells for the expression of CD4, CD8, and DLNGFR. Numbers in the dot plots refer to the percent of DLNGFR-positive cells within the CD4+
or CD8+ cells, respectively. (C) Each dot represents an independent transduction experiment. Transduction rates were determined after 9–13 days as in (B). PBMCs of 6–8
different donors, stimulated either with IL-2 alone or a combination of IL-7 and IL-15, were transduced with 5 or 2.5 mL CD4-LV or CD8-LV, 5 mL VSV-LV, or 1 or 5 mL
BaEV-LV. Two to five batches of vector stock were used (see Table S1 for details). Flow cytometry analysis was performed staining cells for CD4, CD8, LNGFR, and viability.
Results for viability are presented in Figure S2A. Individual results as well as mean values, SDs, and p values are shown. Unpaired t test or Mann-Whitney test was
performed to determine significance. ****p < 0.0001.
www.moleculartherapy.orgafter transduction with and without Vectofusin-1 revealed that
Vectofusin-1 or the transduction process per se only minimally altered
the resulting T cell phenotype ratios, if at all (Figure S2C).
In a next step, we analyzed whether Vectofusin-1 impacts the func-
tionality of the generated CAR T cells with respect to killing of
CD19-positive tumor cells. For this purpose, CAR T cells were gener-
ated with CD8-LV in the presence or absence of Vectofusin-1. Equal
amounts of CAR+ cells were then incubated with carboxyfluorescein
succinimidyl ester (CFSE)-labeled CD19-positive Nalm-6 cells for 4 h
at different effector-to-target ratios. Target cell lysis was determined
by flow cytometry. Both CAR T cell products were able to kill theMoleculNalm-6 tumor cells and showed a significantly higher killing activity
compared to untransduced T cells (Figure 2). Importantly, no
significant difference in target cell lysis was observed for CAR
T cells generated with or without Vectofusin-1 (Figure 2). This result
demonstrates that Vectofusin-1 has no negative influence on the
cytotoxicity of CAR T cells.
DLNGFR Is Present on the Surface of LV Particles and
Transferred to Cells as Protein
To further characterize the off-target signals seen early after transduc-
tion, PBMCs were incubated with vector particles for 1 h at 4C, fol-
lowed by staining for LNGFR and flow cytometry analysis. Underar Therapy: Methods & Clinical Development Vol. 13 June 2019 373
Figure 2. CAR T Cells Generated in the Presence of Vectofusin-1 Are
Functional
A 4-h killing assay of Nalm-6 cells was performed to analyze the cytotoxic function of
CAR T cells transduced with CD8-LV in the presence or absence of Vectofusin-1
(V1). CAR T cells were generated from activated PBMCs (either IL-2 or IL-7 and
IL-15 stimulated) using 5 mL CD8-LV. After the determination of CAR expression,
CAR T cells were mixed with CFSE-labeled Nalm-6 cells in different effector-to-
target ratios as indicated and incubated for 4 h at 37C. The relative percentage of
dead target cells was calculated based on the amount of dead target cells
measured by flow cytometry as a CFSE-positive, viability dye-positive cell popula-
tion. The killing assay was performed twice in three technical replicates. Individual
results as well as mean values, SDs, and p values are shown. One-way ANOVAwas
performed to determine significance. *p < 0.05, **p < 0.005; ns, not significant.
Molecular Therapy: Methods & Clinical Developmentthese conditions transduction and gene expression are not possible.
Signals forDLNGFRwere detected on receptor-positive and -negative
cells in the presence or absence of Vectofusin-1 (Figure 3A; Figure S3).
After incubation with CD4-LV, on average 5% of the CD4-negative
cells and 77% of the CD4-positive cells were DLNGFR positive in
the absence of Vectofusin-1. In the presence of the transduction
enhancer, a significant increase of DLNGFR on CD4-negative cells
was observed, while no significant difference was present for the
CD4-positive compartment.
Similar results were observed for CD8-LV: DLNGFR signals were de-
tected on off-target cells that were incubated with CD8-LV in the pres-
ence of Vectofusin-1 (on average 64%), which were significantly lower
without Vectofusin-1 (on average 4.5%). Interestingly, on-target bind-
ing of CD8-LV to CD8-positive cells was also slightly increased in the
presence of Vectofusin-1 (Figure 3A). For VSV-LV, no significant dif-
ference in DLNGFR signals upon vector binding was observed for
either CD4- or CD8-positive cells (Figure 3A). These results demon-
strated that target-receptor specificity was high for both, CD4-LV
and CD8-LV, in the absence of Vectofusin-1, while the addition of
the transduction enhancer led to the detection of off-target signals after
pure vector binding. Interestingly, in the presence of Vectofusin-1,
binding to off-target cells reached the same level as binding of vector
particles to on-target cells for all LV variants (Figure 3A).
Next, we determined the kinetics of the appearance of DLNGFR sig-
nals on the surface of lymphocytes. For this purpose, vector particles374 Molecular Therapy: Methods & Clinical Development Vol. 13 June 2and cells were incubated for 30 s and up to 60 min in the presence and
absence of Vectofusin-1. Interestingly, the percentage of DLNGFR-
positive cells was similar for each time point and was overall low in
the absence and high in the presence of Vectofusin-1 (Figure 3B).
Already after 30 s, DLNGFR-positive T cells were detected in the
absence and more so in the presence of Vectofusin-1. These signals
only slightly elevated over time in the presence of the transduction
enhancer for both vector types (Figure 3B). Again, binding efficiency
to CD4- and CD8-positive cells was comparable in the presence of
Vectofusin-1, while only target cells were bound in the absence of
the transduction enhancer (Figure S4).
To address whether DLNGFR was incorporated into vector particles,
aDLNGFR-specific ELISA was performed. To quantify the amount of
detected DLNGFR on vector particles, recombinant LNGFR protein
was used as a standard. DLNGFR molecules were detected in all
stocks of vector particles encoding for the CD19-CAR in conjunction
with DLNGFR as reporter, but not in stocks encoding GFP (Table 1;
Figure S5). Calculation of the total amount of DLNGFR molecules
revealed between 169 and 350 DLNGFR molecules per particle
(Table 1).
Next, we were interested whether vector particle binding to off-target
cells required the envelope proteins used for LV pseudotyping. To
study the role of the different envelope components, vector particles
displaying either only the attachment protein, CD4-MV-H or CD8-
NiV-G, or only the fusion protein, MV-F or NiV-F, were generated
(Figure S6). In addition, bald particles harboring no envelope proteins
were produced. The CD19-CAR-DLNGFR construct was used as
transfer vector plasmid. Notably, bald particles harbored by far the
highest amount of DLNGFR per particle (Table S3). Also particles
carrying only one type of the paramyxoviral glycoproteins contained
more DLNGFR than CD4-LV or CD8-LV, respectively (Table 1;
Table S3). Vector particle binding to PBMCs was investigated after
co-incubation for 1 h at 4C in the presence or absence of
Vectofusin-1. Vector binding was detected by staining for DLNGFR
and flow cytometry analysis. As expected, vector particles without
attachment proteins (bald LV, MV-F-LV, or NiV-F-LV) were very
inefficient in cell binding in the absence of the transduction enhancer
(Figure 4). In contrast, sole presentation of a retargeted attach-
ment protein on vector particles (CD4-H-LV or CD8-G-LV) was suf-
ficient to selectively detect DLNGFR on target cells in the absence of
Vectofusin-1 (Figure 4). Interestingly, in the presence of
Vectofusin-1, particle binding to, and thus DLNGFR detection on,
PBMCs was enhanced for all vector types, without any preference
for CD4- or CD8-positive cells (Figure 4), and it was comparable to
the binding rates observed with CD4-LV and CD8-LV particles (Fig-
ure 3). These results demonstrate that Vectofusin-1-mediated attach-
ment of particles to cells is independent of the used envelope proteins.
DISCUSSION
The data presented in this manuscript show that gene transfer into
T lymphocytes by receptor-targeted vectors based on paramyxoviral
glycoproteins can be significantly improved using the transduction019
Figure 3. Vectofusin-1 Mediates DLNGFR Protein Transfer to Non-target Cells
IL-2-stimulated human PBMCs (1  105) were incubated with 10 mL of the indicated vector type in the presence or absence of Vectofusin-1 (V1) at 4C. (A) After 1 h, the
amount ofDLNGFR onCD4- or CD8-positive cells was analyzed by flow cytometry. A representative set of dot plots is presented in Figure S3.Mean values and SDs of at least
8 replicates are shown. Statistical analyses were performed using unpaired t tests. *p < 0.05, ***p < 0.0005, ****p < 0.0001; ns, not significant. (B) Kinetic analysis ofDLNGFR
transfer to T cells. Incubation times ranged from 30 s to 60 min.
www.moleculartherapy.orgenhancer Vectofusin-1. Transduction levels achieved with CD4-LV
and CD8-LV are now comparable to those possible with VSV-LV.
In contrast to the latter, however, transduction with CD4-LV and
CD8-LV is highly selective for the respective T lymphocytes. This
high selectivity as well as target cell killing by the delivered
CD19-CAR was not compromised by Vectofusin-1. In line with
this, its influence on T cell phenotype, viability, and proliferation
capacity of PBMCs was, if detectable at all, only marginal.
Since particle numbers in stocks of CD4-LV and CD8-LV were very
similar to those of VSV-LV, their reduced gene delivery activity in the
absence of Vectofusin-1 must be due to inefficient contact with the
membrane of cultured cells. Vectofusin-1 was previously shown to
assemble into nanofibrils that associate with viral particles, leading
to their sedimentation and, thus, an increased local concentration
at the cell surface.12 This activity of Vectofusin-1 might explain
why, already 30 s after vector addition to cells, a high amount of
cell-bound vector particles was observed in the presence of the trans-
duction enhancer. This effect was independent of the used envelope
protein.
Previous studies investigating the influence of Vectofusin-1 on the
transduction of hematopoietic stem and progenitor cells (HSPCs)
suggested that Vectofusin-1 promotes both the adhesion and the
fusion steps of VSV-LV and GALV-LV with the plasma membrane
of CD34+ cells.9 The CD4- and CD8-targeted LVs applied in our
study revealed that Vectofusin-1 mediates receptor-independent as-
sociation of vector particles with cells, while in its absence only target
receptor-positive cells were bound. Off-target signals present at early
time points after transduction disappeared after prolonged cultiva-
tion. This was not due to death of transduced off-target cells but
rather due to the removal and degradation of the cell-bound vector
particles over extended cell cultivation. Notably, this forced binding
of receptor-targeted vectors to target-receptor-negative cells by
Vectofusin-1 was not accompanied with transduction (Figure 5).
Thus, close vector-cell contact is not sufficient to activate the MV-Moleculor NiV-derived fusion proteins on the vector surface to induce fusion
of the vector particle and host cell membranes.
Interestingly, while Vectofusin-1 was shown to be beneficial for the
transduction of HSPCs with VSV-LV,9 it did not promote gene trans-
fer into T lymphocytes, as demonstrated by our own as well as
previous work.10 This discrepancy in T lymphocyte transduction by
Vectofusin-1 might be explained by the different vector particle entry
pathways. For CD4- and CD8-LV as well as for LV pseudotyped with
glycoproteins from other retroviruses, such as GALV, host cell
binding and fusion occur at the host cell plasma membrane in a
pH-independent manner.13–15 In contrast, VSV-LV is endocytosed
after host cell binding before fusion with endosomal vesicles under
low pH and release into the cytoplasm.16 Although we cannot
completely exclude that differences in the amounts of gene transfer
active particles present in the different vector stocks contributed to
the oppositional effect of Vectofusin-1 on VSV-LV compared to the
receptor-targeted LVs, it is more likely that the different entry modes
are more relevant. Accordingly, if closely related isomers of Vectofu-
sin-1 were used for the transduction of HSPCs with VSV-LV, again,
no or even a negative impact was observed, which was not the case for
GALV-pseudotyped LVs.10 Possibly, Vectofusin-1 reduces the
endocytosis rate of cell surface-bound vector particles. In this respect,
cell-specific differences in endocytosis were observed for nanopar-
ticles dependent on the size and surface properties of those
particles.17–19 Although it is well established that the inhibition of
endocytosis impairs gene delivery with VSV-LV but improves that
of receptor-targeted LVs,20 further studies will have to prove this
hypothesis.
DLNGFR is not only frequently used as a reporter protein for CAR
molecules but also as a cell tracking marker for other therapeutic
transgenes.21 In addition, DLNGFR could be used as a marker to
analyze the behavior of vector cell attachment in the presence and
absence of Vectofusin-1, as it is incorporated in the particle surface
of all generated vectors, including VSV-LV. Incorporation ofar Therapy: Methods & Clinical Development Vol. 13 June 2019 375
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Molecular Therapy: Methods & Clinical Developmentcytosolic proteins, like GFP, in retroviral vector particles is also
possible and responsible for classical protein transfer, so-called pseu-
dotransduction, shortly after vector cell fusion.22 Upon detailed
vector-cell-binding studies and incorporation analysis, we found
that the presence of DLNGFR shortly after transduction is not due
to classical protein transfer. Detection of DLNGFR as soon as 30 s
after co-incubation of PBMCs with vector particles at 4C argues
against membrane fusion having mediated the transfer of DLNGFR
from the packaging cells to the PBMCs. Rather, protein transfer
was mediated by cell-bound vector particles (Figure 5). This effect
was enhanced by Vectofusin-1, which prolonged the period that
vector particles are associated with cells without membrane fusion,
at least on receptor-negative cells.
The incorporation of heterologous viral glycoproteins but also
non-viral transmembrane proteins into LV particles expressed in
the producer cell line has been described before.20,23,24 For envelope
proteins derived from viruses, such as MV or NiV, cytoplasmic tail
truncations have to be performed to allow efficient incorporation
into LV particles.25,26 MV F or NiV F proteins, e.g., have just 5–6
residual C-terminal amino acids when used for pseudotyping.5,25
This is similar to the DLNGFR construct in which the entire cyto-
plasmic domain has been deleted except for 8 amino acids. This phe-
nomenon is also known for HIV-1 or other enveloped viruses, which
can acquire a variety of host cell proteins during particle formation.27
In principle, the incorporation of transmembrane proteins, which are
not encoded on the transgene but expressed during vector production
into fusion-competent LV particles, offers the opportunity to tran-
siently transfer proteins into the host cell membrane upon vector
fusion. This technique might be used to equip cells for a short term
with additional receptors or signaling molecules. Interestingly, our
data also suggest that CARs may become incorporated into the enve-
lope of LV particles. However, detection of the CD19-CAR molecule
in our vector stocks was only possible by western blot analysis, sug-
gesting a lower incorporation rate than for DLNGFR (Figure S7).
Given that the CAR contains a long cytoplasmic tail comprising the376 Molecular Therapy: Methods & Clinical Development Vol. 13 June 24-1BB and CD3zeta domains (154 amino acid [aa]), this was not
surprising. However, it is a possibility with potentially also extensive
consequences for the production of CAR-encoding LV particles.
As a therapeutic outlook, CD8- and CD4-targeted LV particles may
facilitate and improve the generation of CAR T cells in the future,
since only the desired cell population of choice will be transduced.4
T cell purification steps as they are currently typically applied during
the manufacturing process of CAR T cells may then become obsolete.
Beyond that, however, also other therapeutic applications in the
genetic modification of lymphocytes may profit from targeted gene
delivery to lymphocyte subsets.28
MATERIALS AND METHODS
Ethics Statement
The research has been approved by the Ethics Committee of the
University Hospital Frankfurt, Germany. Written informed consent
was obtained from each donor.
Cell Lines and Primary Cells
HEK293T (ATCC: CRL-11268) cells were grown in DMEM (Biowest,
Nuaillé, France), supplemented with 10% fetal calf serum (FCS)
(Biochrom, Berlin, Germany) and 2 mM L-glutamine (Sigma-
Aldrich, Munich, Germany). Molt.4.8 and Nalm-6-EBFP-luc cells
were kindly provided by Dr. Martin Pule, University College of
London (subsequently called Nalm-6 cells), and A301 cells were
grown in RPMI 1640 (Biowest, Nuaillé, France), supplemented with
10% FCS and 2 mM L-glutamine.
Human PBMCs were isolated from the fresh blood of healthy donors
or buffy coats purchased from the German blood donation center
(DRK-Blutspendedienst Hessen, Frankfurt, Germany). 1  107
PBMCs/6-well were activated for 72 h (IL-2 stimulation) or 48 h
(IL-7 and IL-15 stimulation) in RPMI 1640, supplemented with
10% FCS, 2 mM L-glutamine, 0.5% streptomycin and penicillin,
25 mM HEPES (Sigma-Aldrich, Munich, Germany), 3 mg/mL anti-
CD28 antibody (clone 15E8), 1 mg/mL pre-coated anti-CD3 antibody
(clone OKT3), and 100 U/mL IL-2 or 25 U/mL IL-7 and 50 U/mL
IL-15. During and following transduction, cells were cultivated in
the same medium without CD3 antibody and CD28 antibody. All
cytokines and antibodies were from Miltenyi Biotec (Bergisch
Gladbach, Germany).
LV Generation, Concentration, and Titration
Vector particles were generated by transient transfection of HEK293T
cells using polyethylenimine (PEI; Sigma-Aldrich, Munich,
Germany) and second-generation packaging plasmids, as described
before.5,6,29 In brief, 1 day before transfection, 1.5–2  107 cells
were seeded into a T175 flask. In total, 35 mg DNA was added to
2.3 mL DMEM without additives and combined with 2.2 mL
DMEM containing 140 mL 18 mM PEI solution. The transfection
solution was mixed and incubated for 20 min at room temperature.
The cell medium was replaced by 10 mL DMEM, supplemented
with 15% FCS and 3 mM L-glutamine, before the transfection019
Figure 4. Transfer of DLNGFR in the Absence of
Envelope Glycoproteins
10-mL stocks of bald LV particles, CD4-LVs without MV F
protein (CD4-H-LV) or H (MV-F-LV), or CD8-LV without
NiV F protein (CD8-G-LV) or G (NiV-F-LV) were added to
IL-2-stimulated PBMCs (1  105 cells) in the presence or
absence of Vectofusin-1 (V1). After 1 h at 4C, the amount
ofDLNGFR onCD4- andCD8-positive cells was analyzed
by flow cytometry, respectively. The binding assay was
performed at least 6 times showing mean values, SDs,
and p values. Statistical analyses were performed using
unpaired t tests. ***p < 0.0005, ****p < 0.0001; ns, not
significant. A graphical explanation for vector composition
is provided in Figure S6.
www.moleculartherapy.orgsolution was added to HEK293T cells. Then 4–6 h later, the medium
was replaced by DMEM with 10% FCS and 2 mM L-glutamine. At
2 days after transfection, the cell culture supernatant was collected,
and released vector particles were concentrated over a 20% sucrose
cushion at 4,500  g for 24 h. The supernatant was discarded, and
pellets were resuspended in 60 mL Dulbecco’s PBS (Lonza, Cologne,
Germany) per T175 flask.
Plasmid ratios for the generation of CD4- and CD8-receptor-targeted
vector particles as well as particles pseudotyped with the VSV glyco-
protein G or two modified baboon envelope glycoproteins were
described previously5,6,29 and can be found in Table S2. The transfer
plasmid used for packaging encodes for a polycistronic expression
cassette containing the CD19-CAR sequence,11 followed by a P2A
element-linked DLNGFR under the control of a phosphoglycerate
kinase (PGK) promoter. Notably, based on the co-expression of
DLNGFR and the CAR construct, detection of DLNGFR can be
used as surrogate marker for the expression of CAR molecules on
the cell surface. All vectors were titrated on A301 (CD4-LV) or
Molt.4.8 (CD8-LV, CD4-LV, VSV-LV, and BaEV-LV) cells, respec-
tively, as described previously,5 using a LNGFR-specific antibody
for detection. Particle numbers were determined using an HIV-1
p24 antigen ELISA Kit (ZeptoMetrix, Buffalo, NY, USA), according
to the manufacturer’s instructions, by assuming that there is an
average of 2,000 molecules of p24 present per viral particle30 and
that the molecular mass of p24 is 25.587 kDa for HIV-1.31 This
equates to 1.18  1010 viral particles/1 mg p24.
PBMC Transduction
4 104 activated PBMCswere seeded in a 96-well plate in 100 mL of the
normal culture medium containing the appropriate cytokines. TheMolecular Therapy: Methods &transduction enhancer Vectofusin-1 (Miltenyi
Biotec, Bergisch Gladbach, Germany) was used
according to the manufacturer’s instructions. In
brief, Vectofusin-1 was diluted in RPMI without
additives to a final concentration of 40 mg/mL in
50 mL. 1, 2.5, or 5 mL vector stock was filled up
withRPMIwithout additives to the same volume.
For vector particle numbers refer to Table S1.DilutedVectofusin-1 and diluted vector solutionsweremixed and incu-
bated for 5–10 min at room temperature. Subsequently, the transduc-
tion mix was added to the cells. When the transduction was performed
withoutVectofusin-1, 1, 2.5, or 5mL of each vectorwas diluted in 100mL
RPMI without additives and directly added to the cells. For spinfection,
centrifugation at 850  g and 32C for 90 min was performed. After-
ward, the PBMCs were gently resuspended by pipetting. PBMCs
received fresh completemedium every other day after transduction un-
til cell analysis. Notably, after initial activation, no re-stimulation with
extraneous antigen or antibody cocktail was performed. Transgene
expression was determined by flow cytometry 7–13 days post-
transduction if not specified otherwise. Cytotoxic activity was analyzed
in a flow cytometry-based cytotoxicity assay 14 or 15 days post-
transduction.
Cytotoxicity Assay
Cytotoxic activity of CD8-LV-transduced, CD19-CAR-expressing
PBMCs was determined using CD19-positive Nalm-6 cells. To reduce
activity of the PBMCs and enhance their cytotoxic function upon
antigen presentation, the cytokine treatment of transduced PBMCs
was reduced by half 11 or 12 days post-transduction. Then 48 h later,
the cells were analyzed for DLNGFR expression by flow cytometry
before they were used in killing assays on the next day.
5 104 or 1 104 CAR-positive T cells or untransduced T cells were
coincubated with 1 104 Nalm-6 cells, which were previously labeled
with CellTrace CFSE (Thermo Fisher Scientific), according to the
manufacturer’s instructions. To compensate for variations of trans-
duction efficiency, the effector cell population was normalized to an
absolute T cell number by the addition of untransduced PBMCs.
Nalm-6 cells cocultured without effector cells were used as a control.Clinical Development Vol. 13 June 2019 377
Figure 5. WorkingModel for the Transfer ofDLNGFR
fromPackagingCells to Target andNon-target Cells
Potential mechanism of action ofDLNGFR protein transfer
illustrated for CD4-LV. For vector production, the envelope
plasmids encoding for CD4-H andMV-F (shown in red and
gray), the transfer plasmid encoding for CAR-DLNGFR
(shown in blue to lilac), and the packaging plasmid (shown
in green) are transfected into 293T cells. Upon protein
expression, the encoded transmembrane proteins trans-
locate to the 293T plasma membrane. This way, CD4-H
and MV-F as well as DLNGFR, get efficiently incorporated
into the viral surface of the budding vector particle. In the
presence of Vectofusin-1, vector particles bind to CD4-
positive (target) as well as CD4-negative (non-target) cells
due to the stickiness of the transduction enhancer. Anti-
body staining for DLNGFR detects bound vector particles
on receptor-positive as well as receptor-negative cells.
Stable gene transfer, however, is restricted to target cells
(top).
Molecular Therapy: Methods & Clinical DevelopmentCoincubation was performed for 4 h at 37C in a total volume
of 200 mL RPMI medium, supplemented with 10% FCS, 1%
L-glutamine, 0.5% streptomycin/penicillin, and 25 mM HEPES
without cytokines. Afterward, the cell mixture was stained for dead
cells using the fixable viability dye eFluor780, according to the
manufacturer’s instructions, and analyzed by flow cytometry. The
percent of dead target cells was analyzed as the CFSE-positive,
viability dye-positive cell population. The background level of dead
target cells, incubated without T cells, was subtracted to calculate
the relative amount of dead target cells.
Binding Assay
10 mL of various LV particles was diluted in 40 mL medium without
additive and mixed with 2 mL Vectofusin-1 (final concentration
20 mg/mL). Afterward, the mix of vector and Vectofusin-1 was added
to 1  105 IL-2-stimulated PBMCs/96-well. The plate was incubated
for 1 h at 4C. Subsequently, cells were washed twice with washing
buffer (PBS, 2% FCS, and 0.1% NaN3), before vector attachment
was quantified by flow cytometry analyzing DLNGFR detection.
Flow Cytometry
Flow cytometry analysis was performed using the MACSQuant
Analyzer 10 (Miltenyi Biotec, Bergisch Gladbach, Germany) flow cy-
tometer, and data were analyzed by FCS Express 6 (De Novo Software,
Glendale, CA, USA). To determine the percentage of transduced cells
or cell-bound vector particles, staining of up to 1  105 PBMCs was
performed. Viable cells were detected using the fixable viability dye
eFluor780 (Life Technologies, Darmstadt, Germany), according to
the manufacturer’s instructions. To further characterize the PBMCs,
cells were stained with a CD4-specific antibody (clone VIT4) labeled
with VioBlue or phycoerythrin (PE)-Vio770 and a CD8-specific anti-
body (clone BW135/80) labeled with VioGreen or allophycocyanin
(APC). The reporter protein DLNGFR, which is co-expressed with
the CD19-CAR, was detected using a PE-labeled anti-LNGFR anti-
body (clone ME20.4-1.H4). After staining, cells were washed twice378 Molecular Therapy: Methods & Clinical Development Vol. 13 June 2with washing buffer (PBS, 2% FCS, and 0.1% NaN3) and fixed with
PBS containing 1% formaldehyde prior to analysis. All antibodies
were from Miltenyi Biotec (Bergisch Gladbach, Germany).
ELISA
A flat-bottom, 96-well MAXISORPmicroplate (Thermo Fisher Scien-
tific, Darmstadt, Germany) was coated with 0.1 mL of different LV
particles in 100 mL PBS-T (PBS and 0.05% Tween-20). After blocking
the wells with PBS-B (PBS and 0.5% BSA), the biotinylated anti-
LNGFR antibody (clone ME20.4-1.H4, Miltenyi Biotec, Bergisch
Gladbach, Germany) was added. To quantify the amount ofDLNGFR
on the vector particles, wells were incubated with horseradish
peroxidase (HRP)-conjugated streptavidin (Jackson ImmunoResearch
Laboratories, Ely, UK) diluted 1:500 in PBS-T (PBS and 1%
Tween-20). Thereafter, 1-Step Ultra TMB-ELISA substrate (Thermo
Fisher Scientific, Darmstadt, Germany) was used to develop the color
reaction. At the end, 1 N H2SO4 solution was added to stop the
reaction, and measurement was performed at 450 nm and 630 nm
by an ELISA reader. A serial dilution from 0 to 12.5 ng human recom-
binant NGFR (Sino Biological, Wayne, PA, USA) was used to draw
standard curve. All protein or antibody incubation steps were per-
formed for 1 h at room temperature, followed by washing the wells
three times with PBS-T. Each experiment was repeated up to nine
times with technical duplicates.
Statistical Analysis
Statistical analyses were performed with Prism 7 software (GraphPad,
San Diego, CA, USA). Tests for statistical significance used the
unpaired two-tailed Student’s t test, Mann-Whitney test, or one-
way ANOVA (Tukey’s multiple comparisons test) as indicated;
p values less than 0.05 were considered significant.
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